Adial PharmaceuticalsADIL
13F holders, Q3 2025 (September 30)16holders
3new positions
3sold out
1famous investor
$0.35avg. 13F price*
At the end of Q3 2025, 16 institutions reported holding Adial Pharmaceuticals Inc. (ADIL) in their 13F filings, unchanged from Q2 2025. 3 opened new positions and 3 sold out. The largest holders were Geode Capital Management, LLC ($58K), Vanguard Group Inc. ($55K) and Citadel Advisors ($51K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Adial Pharmaceuticals Inc.
- CUSIP
- 00688A205
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $59K |
| Exits | 3 | $5K |
All 13F filers, Q2 2025 → Q3 2025: 411,324 shares bought and 37,945 shares sold, net +373,379 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 16 holders
| Geode Capital Management, LLC | 0.00% | Add +138.4% | 164,127 | $58K |
| Vanguard Group Inc. | 0.00% | Add +1085.7% | 156,024 | $55K |
| Citadel Advisors | 0.00% | New | 143,791 | $51K |
| Manchester Capital Management LLC | 0.00% | No change | 48,097 | $17K |
| BlackRock, Inc. | 0.00% | No change | 27,770 | $10K |
| UBS Group AG | 0.00% | Add +51.3% | 18,758 | $7K |
| Two Sigma Securities, LLC | 0.00% | New | 12,841 | $5K |
| Jane Street Group, LLC | 0.00% | Reduce -50.4% | 12,341 | $4K |
| Private Management Group Inc. | 0.00% | New | 10,000 | $4K |
| HRT Financial LP | 0.00% | Reduce -41.4% | 11,191 | $3K |
| SBI Securities Co., Ltd. | 0.00% | Add +5.9% | 1,396 | $493 |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -3.5% | 1,370 | $484 |
| Bank of America Corp. | 0.00% | Add +149.3% | 182 | $64 |
| Wells Fargo & Company | 0.00% | No change | 160 | $57 |
| Abound Wealth Management | 0.00% | No change | 27 | $10 |
| Morgan Stanley | 0.00% | No change | 9 | $3 |
"% of holder's portfolio" is ADIL's weight in each manager's 13F, not the share of Adial Pharmaceuticals Inc. the manager owns.